Envista Holdings
NVST
23.04
-0.23
-0.99%
Envista Holdings
US · NVST
#2329 by market cap
Listed 2019
23.04
-0.23
-0.99%
Live - 5344 symbols - heartbeat 431s ago
· 2026-10-08 07:16
Pre-market
23.70
+2.86%
After-hours
23.04
0.00%
- Market cap
- 3.70B
- P/E (TTM)i
- 39.72
- P/Bi
- 1.20
- EPSi
- 0.28
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on NVST?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.62, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.32% YoY
Margins
- Gross margin
- 54.67%
- Operating margin
- 8.67%
- Net margin
- 1.73%
Key ratios & quality
- Enterprise valuei
- 3.98B
- Altman Z-Scorei
- 1.62
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.84B | 2.28B | 1.93B | 2.51B | 2.57B | 2.57B | 2.51B | 2.72B |
| Gross profit | 1.60B | 1.35B | 1.05B | 1.43B | 1.47B | 1.44B | 1.37B | 1.49B |
| Selling & admin expenses | 1.13B | 980.40M | 924.60M | 1.02B | 1.03B | 1.03B | 1.14B | 1.14B |
| Research & development | 172.00M | 133.10M | 86.70M | 100.50M | 100.10M | 93.80M | 99.10M | 114.00M |
| Operating profit | 298.40M | 235.70M | 43.50M | 306.20M | 343.20M | 314.90M | 137.20M | 235.80M |
| Pretax profit | 301.10M | 233.70M | -20.00M | 254.50M | 283.90M | -54.90M | -1.08B | 177.20M |
| Tax | 70.40M | 49.60M | -62.50M | -9.00M | 45.90M | 45.30M | 33.90M | 130.20M |
| Net profit | 230.70M | 217.60M | 33.30M | 340.50M | 243.10M | -100.20M | -1.12B | 47.00M |
| Basic EPS | 1 | 2 | 0 | 2 | 1 | -1 | -7 | 0 |
| Diluted EPS | 1.49 | 1.60 | 0.20 | 1.92 | 1.37 | -0.60 | -6.50 | 0.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 616.90M | 682.10M | 669.90M | 750.60M | 705.50M | 730.50M |
| Gross profit | 336.00M | 369.90M | 370.20M | 410.60M | 390.10M | 407.00M |
| Selling & admin expenses | 263.30M | 295.30M | 284.40M | 285.50M | 293.90M | 296.30M |
| Research & development | 25.30M | 28.30M | 28.30M | 32.10M | 30.00M | 30.40M |
| Operating profit | 47.40M | 46.30M | 57.50M | 93.00M | 66.20M | 80.30M |
| Pretax profit | 29.00M | 40.70M | 49.90M | 57.60M | 52.20M | 74.40M |
| Tax | 11.00M | 14.30M | 80.20M | 24.70M | 13.50M | 20.70M |
| Net profit | 18.00M | 26.40M | -30.30M | 32.90M | 38.70M | 53.70M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.10 | 0.16 | -0.18 | 0.20 | 0.23 | 0.33 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 786.80M | 1.00B | 1.59B | 1.84B | 1.42B | 1.74B | 1.79B | 2.03B |
| Cash & ST investments | 0 | 211.20M | 888.90M | 1.07B | 606.90M | 940.00M | 1.07B | 1.21B |
| Inventory | 278.70M | 277.90M | 216.00M | 263.80M | 300.80M | 258.80M | 241.00M | 288.10M |
| Total assets | 5.84B | 6.16B | 6.88B | 6.57B | 6.59B | 6.61B | 5.35B | 5.68B |
| Total current liabilities | 641.00M | 709.20M | 1.68B | 1.21B | 1.24B | 780.80M | 878.70M | 852.60M |
| Short-term debt | -- | 30.60M | 917.90M | 456.10M | 537.00M | 145.60M | 150.50M | 39.00M |
| Long-term debt | -- | 1.32B | 907.70M | 883.40M | 870.70M | 1.40B | 1.28B | 1.45B |
| Total liabilities | 1,015,200,000.00 | 2,615,500,000.00 | 3,155,000,000.00 | 2,516,200,000.00 | 2,380,100,000.00 | 2,431,200,000.00 | 2,415,700,000.00 | 2,572,700,000.00 |
| Total equity | 4.83B | 3.54B | 3.72B | 4.06B | 4.21B | 4.17B | 2.93B | 3.11B |
| Retained earnings | 0 | 93.10M | 126.40M | 466.90M | 731.40M | 631.20M | -487.40M | -440.40M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 1.85B | 1.93B | 1.95B | 2.03B | 1.92B | 1.96B |
| Cash & ST investments | 1.08B | 1.11B | 1.13B | 1.21B | 1.08B | 1.13B |
| Inventory | 261.30M | 281.90M | 290.80M | 288.10M | 300.30M | 290.90M |
| Total assets | 5.47B | 5.66B | 5.64B | 5.68B | 5.58B | 5.60B |
| Total current liabilities | 873.30M | 793.90M | 821.70M | 852.60M | 786.60M | 807.30M |
| Short-term debt | 151.00M | 36.10M | 39.20M | 39.00M | 38.70M | 38.50M |
| Long-term debt | 1.30B | 1.45B | 1.45B | 1.45B | 1.44B | 1.44B |
| Total liabilities | 2,430,300,000.00 | 2,525,400,000.00 | 2,554,300,000.00 | 2,572,700,000.00 | 2,498,500,000.00 | 2,520,800,000.00 |
| Total equity | 3.04B | 3.14B | 3.09B | 3.11B | 3.08B | 3.08B |
| Retained earnings | -469.40M | -443.00M | -473.30M | -440.40M | -401.70M | -348.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 400.10M | 397.50M | 283.90M | 361.60M | 182.70M | 275.70M | 336.50M | 275.70M |
| Depreciation & amortization | 130.00M | 168.10M | 163.10M | 151.90M | 162.10M | 162.60M | 154.50M | 150.70M |
| Free cash flow | 327.90M | 319.70M | 236.20M | 306.90M | 107.00M | 217.50M | 302.70M | 230.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 643.40M | 0 | -- | -- | 0 | 0 | -166.60M |
| Ending cash balance | 0 | 211.20M | 888.90M | 1.07B | 606.90M | 940.00M | 1.07B | 1.21B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 300.00K | 88.70M | 78.70M | 108.00M | -3.30M | 119.20M |
| Depreciation & amortization | 36.30M | 38.60M | 37.80M | 38.00M | 38.30M | 37.20M |
| Free cash flow | -5.60M | 76.40M | 67.90M | 91.70M | -15.80M | 104.30M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -14.60M | -85.70M | -42.00M | -24.30M | -42.70M | -60.30M |
| Ending cash balance | 1.08B | 1.11B | 1.13B | 1.21B | 1.08B | 1.13B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 4.47 | 5.20 | 0.92 | 8.76 | 5.88 | -2.39 | -31.47 | 1.56 |
| ROA %i | 3.70 | 3.63 | 0.51 | 5.06 | 3.69 | -1.52 | -18.71 | 0.85 |
| ROIC %i | 4.47 | 3.85 | 1.46 | 6.77 | 4.89 | -0.92 | -21.03 | 1.62 |
| 5-year avg ROE %i | -- | -- | -- | 5.12 | 5.09 | 3.67 | -3.66 | -3.53 |
| EBIT margin %i | 10.49 | 10.14 | 1.42 | 12.30 | 12.55 | 0.33 | -41.36 | 7.86 |
| FCF / sales %i | 11.53 | 11.62 | 10.35 | 12.23 | 4.16 | 8.47 | 12.06 | 8.47 |
| Current ratioi | 1.23 | 1.41 | 0.94 | 1.52 | 1.15 | 2.23 | 2.04 | 2.38 |
| Quick ratioi | 0.72 | 0.92 | 0.71 | 1.16 | 0.81 | 1.73 | 1.63 | 1.93 |
| Debt / assetsi | 0.00 | 24.97 | 28.77 | 22.21 | 23.21 | 25.04 | 28.93 | 28.13 |
| LT debt / equityi | -- | 42.57 | 28.50 | 24.74 | 23.58 | 36.13 | 47.61 | 50.18 |
| Interest coveragei | -- | 79.71 | 0.52 | 5.70 | 8.39 | 0.13 | -22.38 | 5.84 |
| Revenue CAGR (3Y) %i | -- | -6.39 | -11.79 | -4.10 | 3.99 | 9.98 | 0.02 | 1.91 |
| Net income CAGR (3Y) %i | -- | -7.17 | -52.00 | 13.86 | 3.76 | -- | -- | -42.18 |
| FCF CAGR (3Y) %i | -- | -4.57 | -8.68 | -2.18 | -30.57 | -2.71 | -0.46 | 29.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -31.33 | 1.76 | 0.50 | 1.56 | 2.21 | 3.06 |
| ROA %i | -18.70 | 0.97 | 0.27 | 0.85 | 1.23 | 1.69 |
| ROIC %i | -21.04 | 1.77 | 0.90 | 1.62 | 1.91 | 2.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -41.86 | 6.07 | 7.33 | 7.86 | 8.37 | 9.43 |
| FCF / sales %i | 10.70 | 10.10 | 10.01 | 8.47 | 7.84 | 8.69 |
| Current ratioi | 2.12 | 2.44 | 2.37 | 2.38 | 2.44 | 2.43 |
| Quick ratioi | 1.68 | 1.93 | 1.87 | 1.93 | 1.93 | 1.94 |
| Debt / assetsi | 28.55 | 28.18 | 28.39 | 28.13 | 28.49 | 28.37 |
| LT debt / equityi | 46.42 | 49.70 | 50.61 | 50.18 | 50.35 | 50.37 |
| Interest coveragei | -24.49 | 3.96 | 5.31 | 5.84 | 6.78 | 7.61 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Specialty Products & Technologies is the largest reported line at 64.48% of revenue, across 2 reported segments.
- Equipment & Consumables follows at 35.52%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Specialty Products & Technologies64.48%
Equipment & Consumables35.52%
Quote time 2026-10-08 07:16:28 · For reference only, not investment advice and not tailored to your situation.